Histamina Hal Allergy

Histamina Hal Allergy is a diagnostic preparation that contains histamine dihydrochloride as its active ingredient. It is supplied for cutaneous use in allergy testing, typically as a skin‑prick reagent. The product is marketed in the European Union and is intended to provoke a controlled wheal‑and‑flare response that helps clinicians assess allergic sensitization. No specific strength or dosage form is disclosed for clinical evaluation by physicians.

Histamina Hal Allergy is used as a standardized reagent for skin prick testing to identify IgE‑mediated allergic sensitization.

- Conduct skin prick tests for suspected food, inhalant, or drug allergies. - Provide a positive control reaction to confirm test reliability. - Assist in differentiating between allergic and non‑allergic rhinitis. - Support allergists in determining the need for further immunologic evaluation.

Local and systemic reactions may occur after skin application of Histamina Hal Allergy.

Common: - Redness (erythema) at the test site. - Swelling (wheal) up to 5 mm in diameter. - Itching or mild pruritus around the puncture. - Transient warmth or tingling sensation.

Serious: - Large wheal exceeding 10 mm indicating hypersensitivity. - Severe urticaria extending beyond the test area. - Anaphylactic symptoms such as difficulty breathing, hypotension, or widespread rash. - Persistent edema lasting more than 30 minutes.

When using Histamina Hal Allergy, clinicians should observe several precautionary measures to ensure patient safety.

- Verify patient’s history of severe allergic reactions or anaphylaxis before testing. - Avoid testing on broken, inflamed, or infected skin. - Do not use in patients taking antihistamines or recent corticosteroid therapy without appropriate washout. - Keep the test area under observation for at least 15 minutes after application. - Have emergency equipment and epinephrine readily available. - Document the size of the wheal and compare with control reactions.

Histamina Hal Allergy may interact with medications or conditions that alter histamine pathways or skin reactivity.

Avoid: - Concurrent use of systemic antihistamines (e.g., cetirizine, diphenhydramine) that suppress the wheal‑and‑flare response. - Recent topical antihistamine or corticosteroid creams applied to the test site. - Ongoing treatment with mast‑cell stabilizers (e.g., cromolyn) that may blunt the reaction.

Use with caution: - Patients on low‑dose oral corticosteroids, as the response may be reduced but not absent. - Individuals receiving beta‑blockers, which can affect management of potential anaphylaxis. - Elderly patients with fragile skin, where exaggerated local reactions may occur.